Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"
Bob Milius (talk | contribs) |
(migrate to Confluence) |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
<div class="messagebox cleanup metadata"> | <div class="messagebox cleanup metadata"> | ||
| − | <div style="float: left;">[[Image:OpenHotTopic.GIF|35px| ]]</div> | + | <div style="float: left;">[[Image:OpenHotTopic.GIF|35px| ]]</div>Current version: https://confluence.hl7.org/display/FHIR/BiologicallyDerivedProduct+FHIR+Resource+Proposal |
| − | <div style="background:#F0F0F0"> | + | <br /><div style="background:#F0F0F0"> |
This page documents a [[:category:Pending FHIR Resource Proposal|Pending]] [[:category:FHIR Resource Proposal|FHIR Resource Proposal]] | This page documents a [[:category:Pending FHIR Resource Proposal|Pending]] [[:category:FHIR Resource Proposal|FHIR Resource Proposal]] | ||
</div> | </div> | ||
| Line 34: | Line 34: | ||
==Committee Approval Date:== | ==Committee Approval Date:== | ||
<i>Please enter the date that the committee approved this Resource proposal</i> | <i>Please enter the date that the committee approved this Resource proposal</i> | ||
| + | October 5, 2017 | ||
==Contributing or Reviewing Work Groups== | ==Contributing or Reviewing Work Groups== | ||
<!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | <!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | ||
| − | * [[Patient Care]] | + | *[[Patient Care]] |
| − | * [[Pharmacy]] | + | *[[Pharmacy]] |
==FHIR Resource Development Project Insight ID== | ==FHIR Resource Development Project Insight ID== | ||
| Line 63: | Line 64: | ||
Examples include: | Examples include: | ||
| − | * hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction) | + | |
| − | * blood (whole, extracted cells, plasma, etc) | + | *hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction) |
| − | * organs | + | *blood (whole, extracted cells, plasma, etc) |
| − | * tissues (porcine valves, skin, bovine cardiac tissue, etc.) | + | *organs |
| − | * manipulated cells (e.g. CAR T-cells) | + | *tissues (porcine valves, skin, bovine cardiac tissue, etc.) |
| + | *manipulated cells (e.g. CAR T-cells) | ||
| + | |||
| + | The workflow using this resource (e.g., request, administration) should be discussed and implemented in a consistent way as other similar resources are handled (e.g., device, medication) | ||
==RIM scope== | ==RIM scope== | ||
| Line 94: | Line 98: | ||
<!--Key resources are justified by CCDA, for resources not deemed "key", what interest is there by implementers in using this particular resource. Provide named implementations if possible - ideally provide multiple independent implementations. --> | <!--Key resources are justified by CCDA, for resources not deemed "key", what interest is there by implementers in using this particular resource. Provide named implementations if possible - ideally provide multiple independent implementations. --> | ||
| − | This will be used in reporting clinical outcomes to the Center | + | This will be used in reporting clinical outcomes to the Center for International Blood and Marrow Transplant Research (CIBMTR) after hematopoietic cell transplant (bone marrow, peripheral blood stem cells, cord blood). |
This resource is not used in CCDA. | This resource is not used in CCDA. | ||
==Content sources== | ==Content sources== | ||
| + | For reporting of clinical outcomes to CIBMTR, source data would come from federated systems at the transplant center, e.g., from the EHR, transplant databases, labs | ||
<!-- List all of the specifications (beyond those in the "standard" (FHIR_Design_Requirements_Sources) list of source specifications) that you’re planning to consult | <!-- List all of the specifications (beyond those in the "standard" (FHIR_Design_Requirements_Sources) list of source specifications) that you’re planning to consult | ||
| Line 104: | Line 109: | ||
Are there any source specifications that you wish to consult but are concerned about access to or expertise to consider? --> | Are there any source specifications that you wish to consult but are concerned about access to or expertise to consider? --> | ||
| − | * Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct | + | *Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct |
| − | * Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person | + | *Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person |
| − | * Patient receives post-HCT infusion of donor t-cells (BiologicallyDerivedProduct) | + | *Patient receives post-HCT infusion of donor t-cells (BiologicallyDerivedProduct) |
| − | * Patient receives blood (BiologicallyDerivedProduct) transfusion | + | *Patient receives blood (BiologicallyDerivedProduct) transfusion |
| − | * Patient receives HLA-matched platelets (BiologicallyDerivedProduct) | + | *Patient receives HLA-matched platelets (BiologicallyDerivedProduct) |
| − | * Patient receives heart (BiologicallyDerivedProduct) transplant from deceased donor Patient | + | *Patient receives heart (BiologicallyDerivedProduct) transplant from deceased donor Patient |
| − | * Patient donates kidney (BiologicallyDerivedProduct) for transplantation in another Patient | + | *Patient donates kidney (BiologicallyDerivedProduct) for transplantation in another Patient |
| − | * Patient received pig heart valve (BiologicallyDerivedProduct) | + | *Patient received pig heart valve (BiologicallyDerivedProduct) |
==Resource Relationships== | ==Resource Relationships== | ||
Latest revision as of 14:59, 31 October 2019
This page documents a Pending FHIR Resource Proposal
Contents
- 1 BiologicallyDerivedProduct
- 1.1 Owning committee name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Resource Relationships
- 1.11 Timelines
- 1.12 gForge Users
- 1.13 When Resource Proposal Is Complete
- 1.14 FMG Notes
BiologicallyDerivedProduct
Owning committee name
Committee Approval Date:
Please enter the date that the committee approved this Resource proposal October 5, 2017
Contributing or Reviewing Work Groups
FHIR Resource Development Project Insight ID
1128 Patient Care FHIR resource review
Scope of coverage
A material substance originating from a biological entity intended to be transplanted or infused into another (possibly the same) biological entity.
Examples include:
- hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
- blood (whole, extracted cells, plasma, etc)
- organs
- tissues (porcine valves, skin, bovine cardiac tissue, etc.)
- manipulated cells (e.g. CAR T-cells)
The workflow using this resource (e.g., request, administration) should be discussed and implemented in a consistent way as other similar resources are handled (e.g., device, medication)
RIM scope
No identified mappings to RIM 2.46 objects.
Resource appropriateness
Organs, tissues, and fluids obtained from one biological entity (person or animal) for the purpose of infusion, transplantation or grafting to another biological entity are neither Specimens ("used for diagnostic and environmental testing") nor Devices ("an instance or a type of a manufactured item") nor Medications (drug, ingredients, and packaging) nor Substances ("homogeneous material with a definite composition"). Furthermore, there is established a relationship between two entities, the donor and the recipient.
Expected implementations
This will be used in reporting clinical outcomes to the Center for International Blood and Marrow Transplant Research (CIBMTR) after hematopoietic cell transplant (bone marrow, peripheral blood stem cells, cord blood).
This resource is not used in CCDA.
Content sources
For reporting of clinical outcomes to CIBMTR, source data would come from federated systems at the transplant center, e.g., from the EHR, transplant databases, labs
- Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct
- Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person
- Patient receives post-HCT infusion of donor t-cells (BiologicallyDerivedProduct)
- Patient receives blood (BiologicallyDerivedProduct) transfusion
- Patient receives HLA-matched platelets (BiologicallyDerivedProduct)
- Patient receives heart (BiologicallyDerivedProduct) transplant from deceased donor Patient
- Patient donates kidney (BiologicallyDerivedProduct) for transplantation in another Patient
- Patient received pig heart valve (BiologicallyDerivedProduct)
Resource Relationships
ProcedureRequest (for collection)
Patient ("receiver" and "source")
Practitioner (who collected product)
Substance (product processing)
DiagnosticReport (containing HLA-typing)
BiologicallyDerivedProduct ("parent" product for multi-day collections)
Procedure (one for collection and one for transplantation, will need to add BiologicallyDerivedProduct to the "usedReference")
Timelines
ready by Jan 2018 connectathon
??? voting
gForge Users
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
